Zengwu Wang1, Xin Wang2, Guang Hao3, Zuo Chen2, Linfeng Zhang2, Lan Shao2, Ye Tian2, Ying Dong2, Congyi Zheng2, Yuting Kang2, Runlin Gao4. 1. Division of Prevention and Community Health, National Center for Cardiovascular Disease, Fuwai Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 102308, China. Electronic address: wang.zengwu@nccd.org.cn. 2. Division of Prevention and Community Health, National Center for Cardiovascular Disease, Fuwai Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 102308, China. 3. Georgia Prevention Institute, Medical College of Georgia, Augusta University, Augusta, GA, USA. 4. Department of Cardiology, Fuwai Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100037, China.. Electronic address: gaorunlin@citmd.com.
Abstract
BACKGROUND: Peripheral arterial disease (PAD) is the third leading cause of atherosclerotic vascular morbidity after coronary heart disease and stroke. Epidemiology data of PAD is very limited in low-income and middle-income countries. A national wide survey was conducted from October 2012 to December 2015 to assess the prevalence of PAD in China. METHODS: Data from the China Hypertension Survey (CHS). In total, 56,000 people aged 35 years or older were enrolled in this sub-survey for PAD, and 30,025 participants were eligible for analysis. Ankle-brachial index was measured using an automated ABI device (WatchBP Office device Microlife, China). PAD was defined by ABI and Edinburgh Claudication Questionnaire. RESULTS AND CONCLUSIONS: Overall, 6.6% (estimated 45.3 million) of the Chinese adult population age 35 years or older had PAD. The weighted prevalence of PAD increased significantly after aged ≥75 years. There were no significant differences in PAD prevalence between urban and rural residents, as well as between males and females. Among individuals with PAD, only 4.9% (95% CI: 0%-10.1%) were aware of their condition, 1.9% (95% CI: 0%-4.0%) received revascularization, and 0.2% (95% CI: 0%-0.4%) achieved ABI >0.9. Older age, Han population, current smokers, education level, hypertension, CAD, diabetes, dyslipidemia, and rural residences all were significantly associated with an increased risk of PAD. In China, there is an increasing prevalence of PAD, but the awareness, treatment, and control were very low. Special attention should be paid to prevent and control PAD in China. CLINICAL TRIAL REGISTRATION NUMBER: ChiCTR-ECS-14004641.
BACKGROUND:Peripheral arterial disease (PAD) is the third leading cause of atherosclerotic vascular morbidity after coronary heart disease and stroke. Epidemiology data of PAD is very limited in low-income and middle-income countries. A national wide survey was conducted from October 2012 to December 2015 to assess the prevalence of PAD in China. METHODS: Data from the China Hypertension Survey (CHS). In total, 56,000 people aged 35 years or older were enrolled in this sub-survey for PAD, and 30,025 participants were eligible for analysis. Ankle-brachial index was measured using an automated ABI device (WatchBP Office device Microlife, China). PAD was defined by ABI and Edinburgh Claudication Questionnaire. RESULTS AND CONCLUSIONS: Overall, 6.6% (estimated 45.3 million) of the Chinese adult population age 35 years or older had PAD. The weighted prevalence of PAD increased significantly after aged ≥75 years. There were no significant differences in PAD prevalence between urban and rural residents, as well as between males and females. Among individuals with PAD, only 4.9% (95% CI: 0%-10.1%) were aware of their condition, 1.9% (95% CI: 0%-4.0%) received revascularization, and 0.2% (95% CI: 0%-0.4%) achieved ABI >0.9. Older age, Han population, current smokers, education level, hypertension, CAD, diabetes, dyslipidemia, and rural residences all were significantly associated with an increased risk of PAD. In China, there is an increasing prevalence of PAD, but the awareness, treatment, and control were very low. Special attention should be paid to prevent and control PAD in China. CLINICAL TRIAL REGISTRATION NUMBER: ChiCTR-ECS-14004641.
Authors: Christine Firth; Andrew S Tseng; Mina Abdelmalek; Marlene Girardo; Danish Atwal; Leslie Cooper; Robert McBane; Amy Pollak; David Liedl; Paul Wennberg; Fadi Elias Shamoun Journal: J Am Heart Assoc Date: 2020-05-16 Impact factor: 5.501